Abstract
Fibromyalgia (FM) is a disorder of central pain processing marked by widespread chronic pain together with fatigue, sleep disturbances, cognitive dysfunction, and depressive episodes. Tested treatments have expressed limited efficacy. Oxidative stress plays a role in the pathology of FM, while multiple neurotransmitters are involved in this syndrome. Antidepressants are used as conventional treatment, especially those with double action on serotonin and norepinephrine that leads to an increased risk of a manic switch. It should be noted that fibromyalgia is high-frequency comorbidity in bipolar disorder. This narrative review, given the limited literature, consisted of animal and in vitro studies, which aims to highlight the positive aspects of Hypericum scruglii as a potential remedy against FM. Many in vitro and clinical studies confirm the Hypericum genus as a natural antidepressant resource. The use of Hypericum derivatives in various acute and chronic diseases has been known for a long time. It is reported that the phloroglucinol derivatives from Hypericum longistylum improve and accelerate the differentiation of neural progenitor cells. The advantage of Hypericum scruglii is that it owns greater antioxidant potential than other species of the Hypericum genus. Suggestions for improving the oral bioavailability of very poor water-soluble molecules of hypericum extracts are also described in this paper.
Highlights
Fibromyalgia (FM) is a syndrome characterized by diffuse pain as a crucial symptom with various other symptoms such as anxiety, fatigue, mood disorder, sleep disturbances, cognitive decline, and episodes of depression [1]
Hypericum L. is a genus of flowering plants that belong in the family Hypericaceae
This is evidenced by the fact that it is prescribed to patients and licensed in a number of European countries [20]
Summary
Fibromyalgia (FM) is a syndrome characterized by diffuse pain as a crucial symptom with various other symptoms such as anxiety, fatigue, mood disorder, sleep disturbances, cognitive decline, and episodes of depression [1]. The prevalence of this syndrome is 3% in the societies of western countries, with a predisposition for more frequent occurrence in women [2]. All of this points to the fact that these patients have problems with sensory processing of pain. Better approaches in understanding fibromyalgia and associated conditions took place after researchers realized that these conditions don’t seem to be caused by inflammation or peripheral damage and instead of that begun to analyze the central neural mechanisms, as prototypical central pain syndrome [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
